Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats

References

• Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375:1545-55; PMID:20399493; http://dx.doi.org/10.1016/S0140-6736(10)60206-1
   PubMed Web of Science ®Google Scholar
• Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969; 89:405-21; PMID:4305197
   PubMed Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89:422-34; PMID:4305198
   PubMed Web of Science ®Google Scholar
• van Drunen Littel-van den Hurk S, Mapletoft JW, Arsic N, Kovacs-Nolan J. Immunopathology of RSV infection: prospects for developing vaccines without this complication. Rev Med Virol 2007; 17:5-34; PMID:17004293; http://dx.doi.org/10.1002/rmv.518
   PubMed Web of Science ®Google Scholar
• McGinnes LW, Gravel KA, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Schmidt MR, Morrison TG. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. J Virol 2011; 85:366-77; PMID:20980510; http://dx.doi.org/10.1128/JVI.01861-10
   PubMed Web of Science ®Google Scholar
• Murawski MR, McGinnes LW, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Heaton PM, Fraire AE, Morrison TG. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol 2010; 84:1110-23; PMID:19889768; http://dx.doi.org/10.1128/JVI.01709-09
   PubMed Web of Science ®Google Scholar
• Schmidt MR, McGinnes-Cullen LW, Kenward SA, Willems KN, Woodland RT, Morrison TG. Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory. J Virol 2014; 88:10165-76; PMID:24965456; http://dx.doi.org/10.1128/JVI.01250-14
   PubMed Web of Science ®Google Scholar
• Schmidt MR, McGinnes LW, Kenward SA, Willems KN, Woodland RT, Morrison TG. Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains. J Virol 2012; 86:11654-62; PMID:22896618; http://dx.doi.org/10.1128/JVI.01510-12
   PubMed Web of Science ®Google Scholar
• Cullen LM, Blanco JC, Morrison TG. Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein. J Transl Med 2015; 13:350; PMID:26541285; http://dx.doi.org/10.1186/s12967-015-0705-8
   PubMed Web of Science ®Google Scholar
• Quan FS, Kim Y, Lee S, Yi H, Kang SM, Bozja J, Moore ML, Compans RW. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J Infect Dis 2011; 204:987-95; PMID:21881112; http://dx.doi.org/10.1093/infdis/jir474
   PubMed Web of Science ®Google Scholar
• Kim KH, Lee YT, Hwang HS, Kwon YM, Kim MC, Ko EJ, Lee JS, Lee Y, Kang SM. Virus-like particle vaccine containing the F protein of respiratory syncytial virus confers protection without pulmonary disease by modulating specific subsets of dendritic cells and effector t cells. J Virol 2015; 89:11692-705; PMID:26355098; http://dx.doi.org/10.1128/JVI.02018-15
   PubMed Web of Science ®Google Scholar
• Lee S, Quan FS, Kwon Y, Sakamoto K, Kang SM, Compans RW, Moore ML. Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins. Antiviral Res 2014; 111:129-35; PMID:25239522; http://dx.doi.org/10.1016/j.antiviral.2014.09.005
   PubMed Web of Science ®Google Scholar
• Boukhvalova MS, Prince GA, Blanco JC. The cotton rat model of respiratory viral infections. Biologicals 2009; 37:152-9; PMID:19394861; http://dx.doi.org/10.1016/j.biologicals.2009.02.017
   PubMed Web of Science ®Google Scholar
• Niewiesk S, Prince G. Diversifying animal models: the use of hispid cotton rats (Sigmodon hispidus) in infectious diseases. Lab Anim 2002; 36:357-72; PMID:12396279; http://dx.doi.org/10.1258/002367702320389026
   PubMed Web of Science ®Google Scholar
• Hotard AL, Shaikh FY, Lee S, Yan D, Teng MN, Plemper RK, Crowe JE, Jr., Moore ML. A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology 2012; 434:129-36; PMID:23062737; http://dx.doi.org/10.1016/j.virol.2012.09.022
   PubMed Web of Science ®Google Scholar
• Hwang HS, Lee YT, Kim KH, Park S, Kwon YM, Lee Y, Ko EJ, Jung YJ, Lee JS, Kim YJ, et al. Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease. Virology 2016; 494:215-24; PMID:27123586; http://dx.doi.org/10.1016/j.virol.2016.04.014
   PubMed Web of Science ®Google Scholar
• Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997; 176:1215-24; PMID:9359721; http://dx.doi.org/10.1086/514115
   PubMed Web of Science ®Google Scholar
• Siber GR, Leombruno D, Leszczynski J, McIver J, Bodkin D, Gonin R, Thompson CM, Walsh EE, Piedra PA, Hemming VG, et al. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis 1994; 169:1368-73; PMID:8195619; http://dx.doi.org/10.1093/infdis/169.6.1368
   PubMed Web of Science ®Google Scholar
• Glenn GM, Fries LF, Thomas DN, Smith G, Kpamegan E, Lu H, Flyer D, Jani D, Hickman SP, Piedra PA. A Randomized, Blinded, Controlled, Dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. J Infect Dis 2015; 213(3):411-22; PMID:26259809
   PubMed Web of Science ®Google Scholar
• Glenn GM, Smith G, Fries L, Raghunandan R, Lu H, Zhou B, Thomas DN, Hickman SP, Kpamegan E, Boddapati S, et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 2013; 31:524-32; PMID:23153449; http://dx.doi.org/10.1016/j.vaccine.2012.11.009
   PubMed Web of Science ®Google Scholar
• Hwang HS, Kwon YM, Lee JS, Yoo SE, Lee YN, Ko EJ, Kim MC, Cho MK, Lee YT, Jung YJ, et al. Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis. Antiviral Res 2014; 110:115-23; PMID:25110201; http://dx.doi.org/10.1016/j.antiviral.2014.07.016
   PubMed Web of Science ®Google Scholar
• Johnson TR, Johnson JE, Roberts SR, Wertz GW, Parker RA, Graham BS. Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J Virol 1998; 72:2871-2880; PMID:9525607
   PubMed Web of Science ®Google Scholar
• Olson MR, Varga SM. CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. J Immunol 2007; 179:5415-24; PMID:17911628; http://dx.doi.org/10.4049/jimmunol.179.8.5415
   PubMed Web of Science ®Google Scholar
• Varga SM, Wissinger EL, Braciale TJ. The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses. J Immunol 2000; 165:6487-95; http://dx.doi.org/10.4049/jimmunol.165.11.6487
   PubMed Web of Science ®Google Scholar
• Monick MM, Powers LS, Hassan I, Groskreutz D, Yarovinsky TO, Barrett CW, Castilow EM, Tifrea D, Varga SM, Hunninghake GW. Respiratory syncytial virus synergizes with Th2 cytokines to induce optimal levels of TARC/CCL17. J Immunol 2007; 179:1648-58; PMID:17641031; http://dx.doi.org/10.4049/jimmunol.179.3.1648
   PubMed Web of Science ®Google Scholar
• Alwan WH, Kozlowska WJ, Openshaw PJ. Distinct types of lung disease caused by functional subsets of antiviral T cells. J Exp Med 1994; 179:81-9; PMID:8270885; http://dx.doi.org/10.1084/jem.179.1.81
   PubMed Web of Science ®Google Scholar
• Castilow EM, Olson MR, Meyerholz DK, Varga SM. Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus. J Virol 2008; 82:2196-207; PMID:18094193; http://dx.doi.org/10.1128/JVI.01949-07
   PubMed Web of Science ®Google Scholar
• Hussell T, Pennycook A, Openshaw PJ. Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur J Immunol 2001; 31:2566-73; PMID:11536154; http://dx.doi.org/10.1002/1521-4141(200109)31:9%3c2566::AID-IMMU2566%3e3.0.CO;2-L
   PubMed Web of Science ®Google Scholar
• Matsuda K, Tsutsumi H, Sone S, Yoto Y, Oya K, Okamoto Y, Ogra PL, Chiba S. Characteristics of IL-6 and TNF-alpha production by respiratory syncytial virus-infected macrophages in the neonate. J Med Virol 1996; 48:199-203; PMID:8835355; http://dx.doi.org/10.1002/(SICI)1096-9071(199602)48:2%3c199::AID-JMV13%3e3.0.CO;2-A
   PubMed Web of Science ®Google Scholar
• Roe MFE, Bloxham DM, Cowburn AS, O'Donnell DR. Changes in helper lymphocyte chemokine receptor expression and elevation of IP-10 during acute respiratory syncytial virus infection in infants. Pediatr Allergy Immunol 2011; 22:229-34; PMID:20561238; http://dx.doi.org/10.1111/j.1399-3038.2010.01032.x
   PubMed Web of Science ®Google Scholar
• Prince GA, Curtis SJ, Yim KC, Porter DD. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 2001; 82:2881-8; PMID:11714962; http://dx.doi.org/10.1099/0022-1317-82-12-2881
   PubMed Web of Science ®Google Scholar
• Meyerholz DK, Griffin MA, Castilow EM, Varga SM. Comparison of histochemical methods for murine eosinophil detection in an RSV vaccine-enhanced inflammation model. Toxicol Pathol 2009; 37:249-55; PMID:19181630; http://dx.doi.org/10.1177/0192623308329342
   PubMed Web of Science ®Google Scholar
• Stokes KL, Chi MH, Sakamoto K, Newcomb DC, Currier MG, Huckabee MM, Lee S, Goleniewska K, Pretto C, Williams JV, et al. Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J Virol 2011; 85:5782-93; PMID:21471228; http://dx.doi.org/10.1128/JVI.01693-10
   PubMed Web of Science ®Google Scholar
• Blanco JC, Richardson JY, Darnell ME, Rowzee A, Pletneva L, Porter DD, Prince GA. Cytokine and chemokine gene expression after primary and secondary respiratory syncytial virus infection in cotton rats. J Infect Dis 2002; 185:1780-5; PMID:12085325; http://dx.doi.org/10.1086/340823
   PubMed Web of Science ®Google Scholar